Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS721 in IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy
NCT02682407Phase 2Terminated
- Sponsor
- Omeros Corporation
- Start
- Mar 2016
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2 trial of narsoplimab in IgA nephropathy (IgAN), lupus nephritis (LN), membranous nephropathy (MN) and 1 more (2 arms), sponsored by Omeros Corporation. Primary endpoints: Proportion of Participants With Treatment Related Adverse Events at 104 weeks and Change From Baseline in Serum and Urine Complement Component Levels at 38 weeks. Started Mar 2016; status: terminated.
02
Drugs
narsoplimab
03
Conditions
IgA nephropathy (IgAN)lupus nephritis (LN)membranous nephropathy (MN)Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT02682407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682407.